aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

Rhea-AI Summary

aTyr Pharma, Inc. (Nasdaq: LIFE) announced plans to report its fourth quarter and full year 2022 financial results on March 9, 2023, after market close. The company will host a conference call and webcast at 5:00 p.m. EST to discuss these results and provide a corporate update. aTyr focuses on developing first-in-class medicines through its tRNA synthetase biology platform, specifically targeting fibrotic lung disease with its clinical-stage candidate, efzofitimod, which modulates immune responses. This conference is a crucial opportunity for investors to gain insights into the company's operational developments and financial performance.

Positive

• Focus on efzofitimod, a clinical-stage candidate targeting fibrotic lung disease.
• Proprietary tRNA synthetase biology platform supports innovative medicine development.

Negative

• None.

Management to host conference call and webcast on March 9th at 5:00 pm EST / 2:00 pm PST

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Date: Thursday, March 9, 2023
Time: 5:00 p.m. EST / 2:00 p.m. PST
Dial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051051ef9145
Webcast Registration: http://investors.atyrpharma.com/events-and-webcasts

Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team at investorrelations@atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.

Contact:

Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

When will aTyr Pharma report its financial results for 2022?

aTyr Pharma will report its fourth quarter and full year 2022 financial results on March 9, 2023.

What time is aTyr Pharma's conference call on March 9, 2023?

The conference call will take place at 5:00 p.m. EST / 2:00 p.m. PST.

How can I access the conference call and webcast for aTyr Pharma?

You can register for the conference call and access the webcast through the links provided in their press release.

What is the focus of aTyr Pharma's research?

aTyr Pharma focuses on developing first-in-class medicines using its proprietary tRNA synthetase biology platform.

What is efzofitimod?

Efzofitimod is a clinical-stage product candidate developed by aTyr Pharma aimed at treating fibrotic lung disease.